If the optimal environment for an effective anti-tumour immune response requires a CAF compartment that is both smaller and devoid of LRRC15+ CAFs, our data strongly suggest that depleting LRRC15+ CAFs themselves may be a more attractive therapeutic strategy to generate robust and durable responses to cancer immunotherapy. The gene discussed is LRRC15; the disease is neoplasm.